BU-NOT-SET

CONTACT US
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Extractables & leachables testing
  • Analytical chemistry
Product mix
Fact sheet
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
  • Industry trends
Eyes
Insight
Global expansion in the CDMO field
  • Industry trends
Eyes
Insight
Insight
  • Analytical chemistry
  • Industry trends
An expert’s guide to analytical services
Insight
  • Drug product
  • Manufacturing
How lyophilisation can help overcome mRNA stability challenges
Insight
  • Drug product
  • Manufacturing
How pre-filled syringes are changing drug delivery of biologics
Webinar
  • Drug product
Choosing the right sterile container for your drug product
Video
  • Manufacturing
ReciBioPharm is advancing the future of xRNA manufacturing
Webinar
  • Biologics
  • Manufacturing
Faster, smaller, smarter: Intelligent manufacturing of mRNA through the power of process analytical technologies
Insight
  • Biologics
ReciBioPharm: The Economic Case for Continuous Manufacturing
Insight
  • Drug product
  • Manufacturing
The innovation bottleneck: Why drug development is so tough, and how connectivity and predictive analysis can overcome obstacles
Insight
  • Industry trends
What are the key trends shaping drug development in 2025?